scholarly journals Multicenter randomized open study of the effectiveness of changed life quality and therapy with angiotensin-converting enzyme inhibitors (quinapril) in obese patients with arterial hypertension (ECO)

2003 ◽  
Vol 9 (6) ◽  
pp. 196-198
Author(s):  
Yu. N. Belenkov ◽  
I. Ye. Chazova ◽  
V. B. Mychka
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Arterial Hypertension ◽  
Antihypertensive Therapy ◽  
Enzyme Inhibitor ◽  
Antihypertensive Drugs ◽  
Main Task ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Increased Risk

The wide spread of obesity in the populate in, and the increased risk of cardiovascular events, and type 2 diabetes mellitus (DM) in this group of patients served as the basis of the ECO study. Therapeutic approaches to treating arterial hypertension (AH) in patients with metabolic syndrome and type 2 DM have their peculiarities. Properly chosen antihypertensive therapy may also contribute to not only its good antihypertensive effect, but to better carbohydrate and lipid metabolic parameters. A decrease in weight may lead to the lowering of blood pressure and to the normalization of metabolic disorders. Obesity is pathogenetically related to AH, and it is apparent that the use of the newest and effective antihypertensive drugs will not be rather effective without concurrent treatment of obesity. But the main task of the study was to provide an opportunity to physician to be, from his/her own experience, convinced of the effectiveness of nondrug measures and their combination with antihypertensive therapy with the drug of choice (the angiotensin-converting enzyme inhibitor quinapril) in treating this group of patients. With this study, the authors would like to pay the attention of physicians and patients to the problem of obesity and All and to the hazard presented by these diseases.

scholarly journals AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR AND CALCIUM ANTAGONIST COMBINATION IN PHARMACOTHERAPY OF ARTERIAL HYPERTENSION

2014 ◽  
Vol 13 (1) ◽  
pp. 64-68
Author(s):  
L. L. Kirichenko ◽  
S. V. Gatsura ◽  
A. N. Golosova ◽  
K. V. Ovsyannikov ◽  
O. V. Budik ◽  
...  
Keyword(s):  
Calcium Antagonist ◽  
Endothelial Dysfunction ◽  
Combination Therapy ◽  
Angiotensin Converting Enzyme ◽  
Arterial Hypertension ◽  
Enzyme Inhibitors ◽  
Enzyme Inhibitor ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

The paper focuses on the justification for preferential administration of antihypertensive combination therapy. Pharmacotherapeutic features of starting the treatment with a combination of angiotensin-converting enzyme inhibitors (ACEI) and calcium antagonists (AC) are reviewed. The authors also present the latest evidence on the ACEI/AC combination effects on such vascular parameters as microcirculation and endothelial dysfunction.

scholarly journals Perindopril is angiotensin-converting enzyme inhibitor in treatment patients with arterial hypertension

2014 ◽  
Vol 11 (3) ◽  
pp. 74-80
Author(s):  
A I Martynov ◽  
I V Urlaeva ◽  
Ye V Akatova ◽  
O P Nikolin
Keyword(s):  
Myocardial Infarction ◽  
Calcium Antagonist ◽  
Angiotensin Converting Enzyme ◽  
Arterial Hypertension ◽  
Angiotensin Converting Enzyme Inhibitor ◽  
Cardiovascular Mortality ◽  
Enzyme Inhibitor ◽  
Antihypertensive Drugs ◽  
Converting Enzyme ◽  
Patients Acceptance

According to the 2013 ESH guidelines, it is possible to use any group of known antihypertensive drugs in the treatment of arterial hypertension. But we often have been using different combinations of drugs. In this situation, using drugs combination in fixed dosage increases patients acceptance of therapy and makes treatment easier. According to the results of the numerous studies, perindopril statistically significant reduces total and cardiovascular mortality and the incidence of myocardial infarction. The combination of perindopril and calcium antagonist makes the drug more effective.

scholarly journals Is it an advantage or disadvantage to usage angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in COVID-19 patients?

2020 ◽  
Vol 8 (12) ◽  
pp. 4200
Author(s):  
Feridun Gurlek ◽  
Eyyüp Tasdemir
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Calcium Channel ◽  
Calcium Channel Blocker ◽  
Beta Blocker ◽  
Channel Blocker ◽  
Enzyme Inhibitor ◽  
Antihypertensive Drugs ◽  
Severe Pneumonia ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors

Background: The use of angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) is an important problem for clinicians who treat coronavirus disease (COVID-19) in patients with hypertension. The aim of the study was to reduce the confusion in this matter to some extent.Methods: This study was carried out in the Health Sciences University, Bursa High Specialization Training and Research Hospital between 23 March to 23 June 2020. Patients were evaluated using thorax computed tomography (CT) taken during hospitalization with severity and risk scoring, confusion, uraemia, respiratory rate, blood pressure, age ≥65 years, score >2 (CURB-65) for pneumonia.Results: The rate of severe pneumonia was significantly higher in the group using ACEI and ARBs. CURB 65 high risk observation rate was significantly higher in the group with ACEI and ARB using. The rate of severe pneumonia observed was significantly higher in the any antihypertensive drugs using group. This risk height is more pronounced in those using ACEI and ARBs. The mortality rate of our 500 patients with COVID-19 was 2.2% (11/500). There was no history of hypertension in these 4 patients, but 1 (1/4) of these 4 patients had diabetes. Six patients were taking ACEI and/or ARB in combination with their diuretic, calcium channel blocker and beta blocker. Only one patient was taking calcium channel blocker and beta blocker.  Conclusions: The risk of severe pneumonia may increase in COVID-19 positive patients using any antihypertensive drug. It was more pronounced in those using ACEI and ARB. We believe that more comprehensive studies are needed in this about.

Angiotensin-converting enzyme inhibitors included in calcium-phosphate nanoparticles as promising drugs for reducing intraocular pressure

2021 ◽  
pp. 62-65
Author(s):  
O.A. Lisovskaya ◽  
◽  
O.V. Beznos ◽  
V.E. Tikhomirova ◽  
T.A. Pavlenko ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Calcium Phosphate ◽  
Angiotensin Converting Enzyme ◽  
Beta Blocker ◽  
Enzyme Inhibitor ◽  
Antihypertensive Drugs ◽  
Eye Drops ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitors ◽  
Calcium Phosphate Nanoparticles

Purpose. To find out the possibility of using angiotensin-converting enzyme (ACE) inhibitors included in calcium-phosphate nanoparticles (CFPs) to reduce intraocular pressure (IOP). Material and methods. Preparation of calcium-phosphate nanoparticles, introduction of ACEI in them, comparative evaluation of the action of enalaprilat, lisinopril and the beta-blocker timolol in the composition of CPF by determining their effect on intraocular pressure in rabbits. Results. Enalaprilat, lisinopril and the beta-blocker timolol in the composition of CPF statistically more significantly reduce intraocular pressure compared to simple solutions of these drugs. Conclusion. The introduction of drugs that reduce IOP into the CPF increases their bioavailability with the instillation method of administration, while their biological activity is preserved, and the effectiveness of the therapeutic effect increases. The results indicates the prospects of using CFPs to include ocular antihypertensive drugs used in the form of eye drops. Key words: calcium-phosphate nanoparticles, angiotensin-converting enzyme inhibitor, intraocular pressure.

scholarly journals Prevention of cardiovascular events at patients with arterial hypertension at treatmentangiotensin-converting enzyme inhibitor.

2009 ◽  
Vol 6 (3) ◽  
pp. 12-17
Author(s):  
Oksana Andreevna Kislyak ◽  
Svetlana Vladimirovna Postnikova
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Arterial Hypertension ◽  
Angiotensin Converting Enzyme Inhibitor ◽  
Ace Inhibitors ◽  
Cardiovascular Events ◽  
Enzyme Inhibitor ◽  
Antihypertensive Drugs ◽  
Converting Enzyme ◽  
Converting Enzyme Inhibitor

Angiotensin-converting enzyme inhibitor is one of basic antihypertensive drugs for treatment of arterial hypertension at first stages of the disease. The review summarizes the data on different ACE inhibitors.

Domestic practice of antihypertensive treatment of diabetic hypertensive patients

2014 ◽  
Vol 155 (43) ◽  
pp. 1695-1700
Author(s):  
Veronika Szentes ◽  
Gabriella Kovács ◽  
Csaba András Dézsi
Keyword(s):  
Blood Pressure ◽  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Enzyme Inhibitor ◽  
Beta Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Patients With Diabetes

Diabetes mellitus as comorbidity is present in 20–25% of patients suffering from high blood pressure. Because simultaneous presence of these two diseases results in a significant increase of cardiovascular risk, various guidelines focus greatly on the anti-hyperintensive treatment of patients with diabetes. Combined drug therapy is usually required to achieve the blood pressure target value of <140/85 mmHg defined for patients with diabetes, which must be based on angiotensin converting enzyme-inhibitors or angiotensin receptor blockers. These can be/must be combined with low dose, primarily thiazid-like diuretics, calcium channel blockers with neutral metabolic effect, and further options include the addition of beta blockers, imidazolin-l-receptor antagonists, or alpha-1-adrenoreceptor blockers. Evidence-based guidelines are obviously present in local practice. Although most of the patients receive angiotensin converting enzyme-inhibitor+indapamid or angiotensin converting enzyme-inhibitor+calcium channel blocker combined therapy with favorable metabolic effects, yet the use of angiotensin converting enzyme-inhibitors containing hidrochlorotiazide having diabetogenic potencial, and angiotensin receptor blocker fixed combinations is still widespread. Similarly, interesting therapeutic practice can be observed with the use of less differentiated beta blockers, where the 3rd generation carvediolol and nebivolol are still in minority. Orv. Hetil., 2014, 155(43), 1695–1700.

Angioedema induced by angiotensin-converting enzyme inhibitors: an analysis of hospitalizations during the COVID-19 pandemic

2021 ◽  
Author(s):  
Tatsiana М. Sabalenka ◽  
Volha V. Zakharava ◽  
Natallia R. Prakoshyna
Keyword(s):  
Angiotensin Converting Enzyme ◽  
Enzyme Inhibitors ◽  
Enzyme Inhibitor ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Converting Enzyme Inhibitors ◽  
Converting Enzyme ◽  
Angiotensin Receptor ◽  
Converting Enzyme Inhibitors ◽  
Converting Enzyme Inhibitor ◽  
Receptor Blockers

Backgraund: The pathogenesis of angioedema induced by angiotensin-converting enzyme inhibitors is based on the accumulation of bradykinin as a result of angiotensin-converting enzyme blockade. The SARS-CoV-2 virus by binding to the angiotensin-converting enzyme 2 receptor, may inhibit its production, which in turn leads to an increase in bradykinin levels. Thus, infection with SARS-CoV-2 may be a likely trigger for the development of angioedema. Aims: to analyze the cases of hospitalizations of patients with angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers during the COVID-19 pandemic. Materials and methods: a retrospective analysis of the medical records of inpatient patients admitted to the Vitebsk Regional Clinical Hospital in May-December 2020 with isolated (without urticaria) angioedema while receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was performed. All patients received smears from the naso- and oropharynx for COVID-19 by polymerase chain reaction. Results: there were admitted 15 patients (9 men and 6 women) aged 44-72 years for emergency indications, which was 53.6% among all patients with isolated angioedema. In two cases, a concomitant diagnosis of mild COVID-19 infection was established with the predominance symptoms of angioedema in the clinical picture with localization in the face, tongue, sublingual area, soft palate. All patients had a favorable outcome of the disease. Conclusions: patients with аngiotensin-converting enzyme inhibitor-induced angioedema may need to be hospitalized to monitor upper respiratory tract patency. There were cases of a combination of аngiotensin-converting enzyme inhibitor-induced angioedema and mild COVID-19 infection. Issues requiring additional research: the effect of SARS-CoV-2 infection on the levels of bradykinin and its metabolites; the trigger role of COVID-19 infection in the development of angioedema in patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; recommendations for the management of patients with аngiotensin-converting enzyme inhibitor-induced angioedema and a positive result for COVID-19.

Sign in / Sign up

Export Citation Format

Share Document